Aclaris (ACRS) Reports Third Quarter 2016 Financial Results
11/3/2016 10:49:14 AM
MALVERN, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced financial results for the third quarter and nine months ended September 30, 2016 and provided an update on its clinical development programs.
“During the third quarter we continued to advance our pipeline programs across a broad range of dermatological diseases. We reported positive results from the Wart-201 Phase 2 study and are planning the next clinical development steps. The company recently submitted an investigational new drug application (IND) for our drug candidate ATI-50001 for the oral treatment of alopecia totalis and alopecia universalis. We also look forward to reporting the results from our Phase 3 clinical trials for our lead drug candidate A-101 Topical Solution (A-101) for the treatment of seborrheic keratosis (SK) in the coming weeks,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.
comments powered by